Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.71 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.64 |
| ▸ | BAD | Q92934 | 1/20 | 0.64 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | RXRA | P19793 | 2/20 | 0.58 |
| ▸ | RXRB | P28702 | 2/20 | 0.58 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 2/20 | 0.54 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363389 | 1.00 | KMO (0.71) | KMOBCL2L1BADMRGPRX4LMNA | |
| SCHEMBL14683877 | 0.90 | KMO (0.87) | KMOLMNAGAARXRARXRB | |
| SCHEMBL29577419 | 0.90 | KMO (0.87) | KMOLMNAGAARXRARXRB | |
| SCHEMBL3220396 | 0.88 | KMO (0.91) | KMOLMNAGAARXRARXRB | |
| SCHEMBL437537 | 0.88 | KMO (0.91) | KMOLMNAGAARXRARXRB | |
| SCHEMBL121809 | 0.86 | KMO (0.68) | KMORXRARXRBKAT6AERN1 | |
| SCHEMBL29904703 | 0.86 | KMO (0.80) | KMOLMNAGAARXRARXRB | |
| SCHEMBL3551496 | 0.86 | KMO (0.80) | KMOLMNAGAARXRARXRB | |
| SCHEMBL69066 | 0.86 | KMO (0.80) | KMOLMNAGAARXRARXRB | |
| SCHEMBL10768172 | 0.86 | KMO (0.80) | KMOLMNAGAARXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117623975-A | Allyl-containing alpha-quaternary carbon secondary amine compound and oxazine compound synthesized by same and containing quaternary carbon center | 扬州大学 | 2024-03-01 | — | — | CN | claimed |
| EP-1910316-B1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-11-10 | — | — | EP | claimed |
| EP-1910316-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-16 | — | — | EP | claimed |
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | US | claimed |
| US-7268154-B2 | Substituted triazole compounds | HOFFMAN-LA ROCHE INC. (US) | 2007-09-11 | — | — | US | claimed |
| WO-2007012579-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | WO | claimed |
| US-20070021475-A1 | Substituted triazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-01-25 | — | — | US | claimed |
| WO-2006060762-A2 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| CN-117623975-A | Allyl-containing alpha-quaternary carbon secondary amine compound and oxazine compound synthesized by same and containing quaternary carbon center | 扬州大学 | 2024-03-01 | — | — | CN | disclosed |
| US-11905273-B2 | Inhibitors for the B-catenin/B-cell lymphoma 9 (BCL9) protein-protein interaction | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-11840533-B2 | Pyridinone-based epigenetic modifiers and uses thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-12-12 | — | — | US | disclosed |
| EP-0699185-B1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
| US-5824691-A | CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-20 | — | — | US | disclosed |
| CN-1123545-A | Guanidine derivatives as inhibitors of Na+/H+ exchange in cells | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-05-29 | — | — | CN | disclosed |
| EP-0699185-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994026709-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | HTR5A, HTR2A, HTR3A | KMO 310/4885BCL2L1 3480/4885BAD 3121/4885 |
| US-20070021475-A1 | Substituted triazole derivatives | GPR3, GRIN3A, GRIK3 | KMO 202/4885BCL2L1 3691/4885BAD 1173/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | KMO 1511/4885BCL2L1 3426/4885BAD 369/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | KMO 1668/4885BCL2L1 4374/4885BAD 3838/4885 |
| US-11840533-B2 | Pyridinone-based epigenetic modifiers and uses thereof | BRD1, BRD2, BRD3 | KMO 1491/4885BCL2L1 1636/4885BAD 2452/4885 |
| US-11905273-B2 | Inhibitors for the B-catenin/B-cell lymphoma 9 (BCL9) protein-protein interaction | BCL9, BCL9L, BCL3 | KMO 4423/4885BCL2L1 12/4885BAD 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.